Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Pharmacokinetics
49%
Posaconazole
30%
Voriconazole
28%
Critically Ill Patients
28%
Therapeutic Drug Monitoring
24%
Population Pharmacokinetics (PopPK)
18%
COVID-19
16%
Isavuconazole
16%
Invasive Aspergillosis
16%
Drug Interactions
15%
Target Attainment
14%
Pharmacokinetic Study
14%
Invasive Fungal Disease
14%
Fluconazole
13%
Lamb
12%
Antifungal Therapy
12%
Micafungin
11%
Pharmacodynamics
11%
Azoles
11%
Dosing Regimen
10%
Oncology Patients
10%
Antifungal Drugs
9%
Intensive Care Unit Patients
9%
Anidulafungin
9%
Caspofungin
9%
Plasma Concentration
9%
Aspergillus Fumigatus
8%
Renal Function
8%
Itraconazole
8%
Ciprofloxacin
8%
Pharmacokinetic/pharmacodynamic (PK/PD)
8%
Minimum Inhibitory Concentration
8%
Flucloxacillin
8%
Azole Antifungals
8%
Obesity
8%
Healthy Volunteers
8%
Morbid Obesity
8%
Invasive Fungal Infection
7%
Invasive Pulmonary Aspergillosis
7%
Pulmonary Aspergillosis
7%
Pediatric Patients
7%
Antimicrobial
7%
Fungal Infection
6%
Intensive Care Unit
6%
Tacrolimus
6%
Trough Concentration
6%
Obese Men
6%
Antifungal Agents
6%
Dried Blood Spots
6%
High Dose
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Posaconazole
30%
Voriconazole
25%
Therapeutic Drug Monitoring
22%
Antifungal Agent
20%
Pharmacodynamics
20%
Invasive Aspergillosis
19%
Pyrrole
18%
Infection
16%
Diseases
15%
Isavuconazole
14%
Fluconazole
13%
Amphotericin B
13%
Micafungin
11%
Normal Human
11%
Caspofungin
9%
Antifungal Therapy
8%
Ciprofloxacin
8%
Mycosis
8%
Aspergillus fumigatus
8%
Flucloxacillin
8%
Itraconazole
8%
Anidulafungin
8%
Drug-Drug Interaction
7%
Systemic Mycosis
7%
Antiinfective Agent
7%
Tacrolimus
6%
Vancomycin
6%
Minimum Inhibitory Concentration
6%
Bioavailability
6%
Pharmacokinetic Modeling
5%
Aspergillosis
5%
Volume of Distribution
5%
Clinical Trial
5%
Echinocandin
5%
Prevalence
5%
Lung Aspergillosis
5%
Triazole
5%
Gentamicin
5%
Malignant Neoplasm
5%
Antibiotics
5%
